C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Profitability Summary

Cutia Therapeutics's profitability score is 27/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score
27/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Cutia Therapeutics

Revenue
198.9m CNY
Cost of Revenue
-98.8m CNY
Gross Profit
100.1m CNY
Operating Expenses
-635.6m CNY
Operating Income
-535.5m CNY
Other Expenses
11.2m CNY
Net Income
-524.3m CNY

Margins Comparison
Cutia Therapeutics Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Cutia Therapeutics
HKEX:2487
2.1B HKD
50%
-269%
-264%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
67%
28%
9%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
60%
19%
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
78%
38%
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
86%
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
133.7B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
87%
30%
34%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
89%
-22%
-14%
Country CN
Market Cap 2.1B HKD
Gross Margin
50%
Operating Margin
-269%
Net Margin
-264%
Country FR
Market Cap 6T USD
Gross Margin
0%
Operating Margin
-17 527%
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Operating Margin
28%
Net Margin
9%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Operating Margin
19%
Net Margin
13%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Operating Margin
38%
Net Margin
0%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Operating Margin
40%
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 133.7B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Operating Margin
30%
Net Margin
34%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
Operating Margin
-22%
Net Margin
-14%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Cutia Therapeutics Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Cutia Therapeutics
HKEX:2487
2.1B HKD
-37%
-32%
-37%
-72%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
56%
4%
15%
11%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
56%
5%
9%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
1%
0%
23%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
-3%
-2%
24%
-80%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
133.7B AUD
16%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
17%
13%
13%
16%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-8%
-7%
-12%
-31%
Country CN
Market Cap 2.1B HKD
ROE
-37%
ROA
-32%
ROCE
-37%
ROIC
-72%
Country FR
Market Cap 6T USD
ROE
115%
ROA
-391%
ROCE
275%
ROIC
3 093%
Country US
Market Cap 310.3B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
11%
Country US
Market Cap 141.6B USD
ROE
56%
ROA
5%
ROCE
9%
ROIC
10%
Country US
Market Cap 115.3B USD
ROE
1%
ROA
0%
ROCE
23%
ROIC
13%
Country US
Market Cap 102.4B USD
ROE
-3%
ROA
-2%
ROCE
24%
ROIC
-80%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 133.7B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 77.3B USD
ROE
17%
ROA
13%
ROCE
13%
ROIC
16%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country NL
Market Cap 36.2B EUR
ROE
-8%
ROA
-7%
ROCE
-12%
ROIC
-31%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top